103 related articles for article (PubMed ID: 12630665)
1. Local IFN-gamma therapy of HPV16-associated tumours.
Mikysková R; Bieblová J; Símová J; Indrová M; Jandlová T; Vonka V; Smahel M; Bubeník J; Mendoza L
Folia Biol (Praha); 2003; 49(1):26-32. PubMed ID: 12630665
[TBL] [Abstract][Full Text] [Related]
2. Treatment of minimal residual disease after surgery or chemotherapy in mice carrying HPV16-associated tumours: Cytokine and gene therapy with IL-2 and GM-CSF.
Mikysková R; Indrová M; Símová J; Jandlová T; Bieblová J; Jinoch P; Bubeník J; Vonka V
Int J Oncol; 2004 Jan; 24(1):161-7. PubMed ID: 14654953
[TBL] [Abstract][Full Text] [Related]
3. Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.
Mikysková R; Bubeník J; Vonka V; Smahel M; Indrova M; Bieblová J; Símová J; Jandlová T
Int J Oncol; 2005 Feb; 26(2):521-7. PubMed ID: 15645139
[TBL] [Abstract][Full Text] [Related]
4. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
Indrová M; Bubeník J; Mikysková R; Mendoza L; Símová J; Bieblová J; Jandlová T; Jinoch P; Smahel M; Vonka V; Pajtasz-Piasecka E
Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.
Indrová M; Bieblová J; Jandlová T; Vonka V; Pajtasz-Piasecka E; Reinis M
Int J Oncol; 2006 Jan; 28(1):253-9. PubMed ID: 16328003
[TBL] [Abstract][Full Text] [Related]
6. Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.
Indrová M; Bubeník J; Mikysková R; Vonka V; Smahel M; Zák R; Símová J; Bieblová J; Mendoza L; Jandlová T
Int J Oncol; 2002 Mar; 20(3):643-6. PubMed ID: 11836582
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant cytokine treatment of minimal residual disease after surgical therapy in mice carrying HPV16-associated tumours: cytolytic activity of spleen cells from tumour regressors.
Indrová M; Mikysková R; Jandlová T; Vonka V; Bubeník J; Bieblová J
Folia Biol (Praha); 2003; 49(6):217-22. PubMed ID: 14748435
[TBL] [Abstract][Full Text] [Related]
8. Local cytokine treatment of HPV16-associated tumours results in inhibition of their lung metastases.
Mikysková R; Bubenik J; Mendoza L; Vonka V; Smahel M; Símová J; Jandlová T
Clin Exp Metastasis; 2000; 18(7):581-7. PubMed ID: 11688963
[TBL] [Abstract][Full Text] [Related]
9. MHC class I+ and class I- HPV16-associated tumours expressing the E7 oncoprotein do not cross-react in immunization/challenge experiments.
Símová J; Mikysková R; Vonka V; Bieblová J; Bubeník J; Jandlová T
Folia Biol (Praha); 2003; 49(6):230-4. PubMed ID: 14748438
[TBL] [Abstract][Full Text] [Related]
10. Peritumoral administration of antigen-unstimulated bone marrow-derived dendritic cells inhibits tumour growth.
Mendoza L; Indrová M; Hájková R; Reinis M; Smahel M; Vonka V; Bubeník J; Jandlová T
Folia Biol (Praha); 2000; 46(3):91-7. PubMed ID: 10925779
[TBL] [Abstract][Full Text] [Related]
11. HPV16-associated tumours: therapy of surgical minimal residual disease with dendritic cell-based vaccines.
Reinis M; Indrová M; Mendoza L; Mikysková R; Bieblová J; Bubeník J; Símová J
Int J Oncol; 2004 Oct; 25(4):1165-70. PubMed ID: 15375569
[TBL] [Abstract][Full Text] [Related]
12. Induction of specific anti-tumour immunity by interferon-gamma gene-transferred murine bladder carcinoma MBT-2.
Hiura M; Hashimura T; Watanabe Y; Kuribayashi K; Yoshida O
Folia Biol (Praha); 1994; 40(1-2):49-61. PubMed ID: 7958064
[TBL] [Abstract][Full Text] [Related]
13. MHC class II antigen expression is not induced on murine epidermal keratinocytes by interferon-gamma alone or in combination with tumour necrosis factor-alpha.
Yeoman H; Anderton JG; Stanley MA
Immunology; 1989 Jan; 66(1):100-5. PubMed ID: 15493270
[TBL] [Abstract][Full Text] [Related]
14. Tumour-inhibitory effects of dendritic cells administered at the site of HPV 16-induced neoplasms.
Mendoza L; Bubeník J; Símová J; Korb J; Bieblová J; Vonka V; Indrová M; Mikysková R; Jandlová T
Folia Biol (Praha); 2002; 48(3):114-9. PubMed ID: 12118725
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy and immunotherapy of tumours induced by gene-modified HPV16-transformed cells.
Sobotková E; Dusková M; Smahel M; Holán V; Janousková O; Vonka V
Oncol Rep; 2004 Oct; 12(4):877-83. PubMed ID: 15375516
[TBL] [Abstract][Full Text] [Related]
16. Expression of major histocompatibility complex antigens in squamous cell carcinomas of the head and neck: effects of interferon gene transfer.
Arosarena OA; Baranwal S; Strome S; Wolf GT; Krauss JC; Bradford CR; Carey TE
Otolaryngol Head Neck Surg; 1999 May; 120(5):665-71. PubMed ID: 10229590
[TBL] [Abstract][Full Text] [Related]
17. Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16.
Smahel M; Sobotková E; Bubeník J; Símová J; Zák R; Ludviková V; Hájková R; Kovarík J; Jelínek F; Povýsil C; Marinov J; Vonka V
Br J Cancer; 2001 Feb; 84(3):374-80. PubMed ID: 11225590
[TBL] [Abstract][Full Text] [Related]
18. Depletion of T(reg) cells inhibits minimal residual disease after surgery of HPV16-associated tumours.
Símová J; Bubeník J; Bieblová J; Rosalia RA; Fric J; Reinis M
Int J Oncol; 2006 Dec; 29(6):1567-71. PubMed ID: 17088998
[TBL] [Abstract][Full Text] [Related]
19. Class II transactivator-mediated regulation of major histocompatibility complex class II antigen expression is important for hematopoietic progenitor cell suppression by chemokines and iron-binding proteins.
Broxmeyer HE; Cooper S; Hangoc G; Chang CH
Exp Hematol; 2006 Aug; 34(8):1078-84. PubMed ID: 16863914
[TBL] [Abstract][Full Text] [Related]
20. CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours.
Reinis M; Símová J; Indrová M; Bieblová J; Bubeník J
Int J Oncol; 2007 May; 30(5):1247-51. PubMed ID: 17390028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
